Events, Positive Results, Collaborations, and Appointments - Research Report on NPS, Echo Therapeutics, Merrimack, Cyberonics, and Enanta
NEW YORK, November 29, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Echo Therapeutics, Inc. (NASDAQ: ECTE), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Cyberonics Inc. (NASDAQ: CYBX), and Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
NPS Pharmaceuticals, Inc. Research Report
On November 25, 2013, NPS Pharmaceuticals, Inc. (NPS) announced its participation at the upcoming 2013 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 3, 2013 at 1:40 p.m. ET. NPS reported that the live webcast as well as its replay will be available under the Investors' Calendar of Events on its website. The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP
Echo Therapeutics, Inc. Research Report
On November 26, 2013, Echo Therapeutics, Inc. (Echo Therapeutics) announced positive results from its multi-center clinical trial of the Symphony CGM System in surgical patients in hospital critical care units. According to Echo Therapeutics, the Symphony CGM System met the primary safety and effectiveness endpoints of the trial, which involved the continuous monitoring of glucose levels in 32 subjects in the critical care units at four investigational sites. Robert F. Doman, Executive Chairman and Interim CEO of Echo Therapeutics, said, "We are extremely pleased with the positive results of this trial. Importantly, this was the largest study of Symphony to date and it was the first time that all of the components of the system were used together in a clinical trial. We believe Symphony demonstrated satisfactory safety, accuracy and reliability during the clinical trial to satisfy CE Mark requirements." The Full Research Report on Echo Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/076d_ECTE
Merrimack Pharmaceuticals, Inc. Research Report
On November 26, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that it is teaming up with Actavis plc (Actavis). Merrimack reported that under this collaboration, it will utilize its proprietary nanoliposomal technology platform to develop and manufacture various pharmaceutical products for Actavis to commercialize around the world. The Company informed that it is eligible to receive up to $15.5 million, including $2.0 million upfront and the remainder in committed near-term funding and development, regulatory and commercial milestone payments related to the first product to come out of this collaboration. Merrimack further informed that it also expects to receive a double-digit share of profits on future global sales of any commercialized products derived from the collaboration. Edward J. Stewart, Senior Vice President at Merrimack and President of Merrimack Healthcare Solutions, said, "Under this collaboration, we are able to advance the development of our commercial infrastructure and utilize our manufacturing capacity to generate upside revenue opportunities to help fund our core R&D programs. Actavis is a dynamic company with significant expertise marketing specialty products around the globe, and we think they will be a great partner." The Full Research Report on Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/8bb0_MACK
Cyberonics Inc. Research Report
On November 21, 2013, Cyberonics Inc. (Cyberonics) announced that it will host an Investor and Analyst Meeting on Thursday, December 5, 2013 from 8:30 a.m. ET to approximately 12:00 p.m. ET. Cyberonics reported that the live webcast and replay of the meeting will be accessible through the Investor Relations, Events and Presentations on the website. The Full Research Report on Cyberonics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/ad51_CYBX
Enanta Pharmaceuticals, Inc. Research Report
On November 25, 2013, Enanta Pharmaceuticals, Inc. (Enanta Pharmaceuticals) announced the appointment of Bruce L.A. Carter, Ph. D. to its Board of Directors. According to the Company, Dr. Carter will also serve as a member of the Compensation and the Nominating and Corporate Governance Committees. Enanta Pharmaceuticals further reported that Helmut M. Schuhsler, Ph.D., has resigned from the position of Director. The Full Research Report on Enanta Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.AnalystsCorner.com/r/full_research_report/a066_ENTA
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article